SCHEMBL30148541

CC[C@H](C)[C@H](NC(=O)CNC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(C)=O)[C@@H](C)CC)C(C)C)[C@@H](C)CC)[C@@H](C)O)C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C(N)=O)C(C)C)[C@@H](C)CC

nearest known ligand 0.74

Predicted protein targets (top 7)

	gene	UniProt	supporting neighbours	confidence
▸	NR3C1	P04150	5/20	0.74

▸	PTH1R	Q03431	8/20	0.72

▸	GLP1R	P43220	5/20	0.71

▸	RXFP1	Q9HBX9	2/20	0.71

▸	CCKBR	P32239	1/20	0.71

▸	ECE1	P42892	1/20	0.70

▸	MUS81	Q96NY9	1/20	0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL30744286	0.98	NR3C1 (0.71)	NR3C1PTH1RGLP1RRXFP1CCKBR
SCHEMBL30744278	0.95	GRPR (0.69)	NR3C1PTH1RGLP1RRXFP1CCKBR
SCHEMBL30683162	0.94	GLP1R (0.81)	NR3C1PTH1RGLP1RCCKBRECE1
SCHEMBL30411571	0.94	PTH1R (0.77)	NR3C1PTH1RGLP1RRXFP1CCKBR
SCHEMBL31396476	0.93	PTH1R (0.74)	NR3C1PTH1RGLP1RCCKBRECE1
SCHEMBL29395456	0.93	GLP1R (0.78)	NR3C1PTH1RGLP1RCCKBRECE1
SCHEMBL29357856	0.92	GLP1R (0.77)	NR3C1PTH1RGLP1RCCKBRECE1
SCHEMBL29412274	0.92	GLP1R (0.73)	NR3C1PTH1RGLP1RRXFP1CCKBR
SCHEMBL29540128	0.91	GLP1R (0.79)	NR3C1PTH1RGLP1RRXFP1CCKBR
SCHEMBL29370374	0.90	GLP1R (0.71)	NR3C1PTH1RGLP1RRXFP1CCKBR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-12415835-B2	Peptide-compound cyclization method	CHUGAI SEIYAKU KABUSHIKI KAISHA (JP)	2025-09-16	—	—	US	disclosed
US-20240197877-A1	BINDING PROTEINS RECOGNIZING HA-2 ANTIGEN AND USES THEREOF	TSCAN THERAPEUTICS, INC.	2024-06-20	—	—	US	disclosed
CN-118103049-A	Binding proteins recognizing HA-2 antigen and uses thereof	帝斯肯医疗公司	2024-05-28	—	—	CN	disclosed
EP-4322971-A1	BINDING PROTEINS RECOGNIZING HA-2 ANTIGEN AND USES THEREOF	Tscan Therapeutics, Inc. (US)	2024-02-21	—	—	EP	disclosed
US-11891457-B2	Peptide-compound cyclization method	CHUGAI SEIYAKU KABUSHIKI KAISHA (JP)	2024-02-06	—	—	US	disclosed
WO-2022221478-A1	BINDING PROTEINS RECOGNIZING HA-2 ANTIGEN AND USES THEREOF	TSCAN THERAPEUTICS, INC. (US)	2022-10-20	—	—	WO	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-11891457-B2	Peptide-compound cyclization method	VIP, NGLY1, GLP1R	NR3C1 4084/4885PTH1R 89/4885GLP1R 3/4885
US-12415835-B2	Peptide-compound cyclization method	VIP, NGLY1, GLP1R	NR3C1 4084/4885PTH1R 89/4885GLP1R 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.